Eli Lilly and CompanyLLYNYSE

Overview Intelligence Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 85% recommend buying.

Consensus Rating

Buy

26 analysts·High coverage

85%

Rating Distribution

Strong Buy

00%

Buy

2285%

Hold

415%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 19% higher.

Bear Case

$830.00

-18%

Consensus

$1214.28

+19%

Bull Case

$1350.00

+33%

Price Range26 analysts

Low

Consensus

High

$830.00

$1350.00

Current Target

Current Price

$1017.97

Upside to Target

$196.31

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$34.27(16 analysts)

P/E44x

Current: 44.3x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+15.88%

EPS+21.66%

FY2028

Rev+13.05%

EPS+18.48%

FY2029

Rev+9.73%

EPS+12.15%

Earnings Surprises

Beat rate:83%(10/12 quarters)

Avg surprise:+27.2%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Feb 24, 2026RBC Capital

RBC Capital Starts Eli Lilly (LLY) at Outperform

Target:$1250.00

+19.9%from $1042.15

Feb 19, 2026Barclays

Eli Lilly initiated with an Overweight at Barclays

Target:$1350.00

+31.9%from $1023.22

Feb 10, 2026Loop Capital Markets

Freedom Capital Markets Upgrades Eli Lilly (LLY) to Buy

Target:$1200.00

+17.1%from $1025.00

Feb 5, 2026Scotiabank

Eli Lilly price target raised to $1,300 from $1,165 at Scotiabank

Target:$1300.00

+25.3%from $1037.13

Feb 5, 2026Truist Financial

Eli Lilly price target raised to $1,281 from $1,182 at Truist

Target:$1281.00

+24.7%from $1027.51

Feb 5, 2026Goldman Sachs

Eli Lilly price target raised to $1,260 from $1,145 at Goldman Sachs

Target:$1260.00

+13.8%from $1107.12

Feb 5, 2026Wells Fargo

Eli Lilly price target raised to $1,280 from $1,200 at Wells Fargo

Target:$1280.00

+15.6%from $1107.12

Feb 5, 2026BMO Capital

Eli Lilly price target raised to $1,300 from $1,200 at BMO Capital

Target:$1300.00

+17.4%from $1107.12

Jan 20, 2026Guggenheim

Eli Lilly price target lowered to $1,161 from $1,163 at Guggenheim

Target:$1161.00

+11.8%from $1038.40

Jan 6, 2026UBS

Eli Lilly assumed with a Buy at UBS

Target:$1250.00

+17.5%from $1064.04

Jan 5, 2026Leerink Partners

Eli Lilly (LLY) PT Raised to $1,234 at Leerink Partners

Target:$1234.00

+14.2%from $1080.36

Dec 16, 2025Daiwa

Eli Lilly upgraded to Buy from Neutral at Daiwa

Target:$1230.00

+15.7%from $1062.71

Dec 15, 2025Goldman Sachs

Eli Lilly price target raised to $1,145 from $951 at Goldman Sachs

Target:$1145.00

+10.2%from $1039.04

Dec 10, 2025HSBC

Eli Lilly price target raised to $1,070 from $850 at HSBC

Target:$1070.00

+9.0%from $981.67

Dec 4, 2025BMO Capital

Eli Lilly price target raised to $1,200 from $1,100 at BMO Capital

Target:$1200.00

+16.1%from $1033.56

Dec 3, 2025Guggenheim

Eli Lilly price target raised to $1,163 from $1,036 at Guggenheim

Target:$1163.00

+11.2%from $1046.12

Dec 2, 2025BMO Capital

BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)

Target:$1100.00

+3.9%from $1058.48

Dec 1, 2025National Bank

Eli Lilly price target raised to $1,286 from $950 at BofA

Target:$1286.00

+21.6%from $1057.89

Nov 24, 2025Bernstein

Eli Lilly price target raised to $1,300 from $1,100 at Bernstein

Target:$1300.00

+22.7%from $1059.70

Nov 24, 2025Morgan Stanley

Eli Lilly (LLY) PT Raised to $1,290 at Morgan Stanley

Target:$1290.00

+21.7%from $1059.70

Nov 19, 2025Truist Financial

Eli Lilly price target raised to $1,182 from $1,038 at Truist

Target:$1182.00

+12.6%from $1049.60

Nov 10, 2025Loop Capital Markets

Freedom Capital Markets Downgrades Eli Lilly (LLY) to Hold

Target:$950.00

-2.0%from $969.84

Oct 31, 2025Cantor Fitzgerald

Eli Lilly price target raised to $985 from $925 at Cantor Fitzgerald

Target:$985.00

+17.4%from $839.16

Oct 9, 2025Cantor Fitzgerald

Eli Lilly price target raised to $925 from $825 at Cantor Fitzgerald

Target:$925.00

+9.4%from $845.72

Oct 8, 2025Guggenheim

Eli Lilly price target raised to $948 from $875 at Guggenheim

Target:$948.00

+12.4%from $843.63

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance